Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting

Curis Inc., a biotechnology company focused on the development of emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor, has announced that it will present new clinical and preclinical data at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) from November 19-23, 2025. The presentations will include clinical data on emavusertib and BTKi in primary and secondary central nervous system lymphomas (PCNSL and SCNSL), as well as preclinical data on emavusertib. The results are scheduled to be presented by researchers from institutions including Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic, and the University of Florida. Presentations will cover topics such as genetic mutation profiles, CNS pharmacokinetics, safety and efficacy of drug combinations, and potential efficacy signals in CNS lymphoma patients. The results will be presented at the conference and have not yet been disclosed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE24901) on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)